Thrombopoietin receptor agonist for treating bone marrow aplasia following anti-CD19 CAR-T cells—single-center experience
Ofrat Beyar‐Katz(Rambam Health Care Campus), Ron Ram(Tel Aviv University), Odit Gutwein(Assaf Harofeh Medical Center), Ronen Ben‐Ami(Tel Aviv University), David Shasha(Tel Aviv University), Yael Bar‐On(Tel Aviv University), Odelia Amit(Tel Aviv University), Chava Perry(Tel Aviv University), Rotem Kedar(Meir Medical Center), Irit Avivi(Tel Aviv Sourasky Medical Center), Jonathan Ben‐Ezra(Tel Aviv University), Oleg Pikovsky(Ben-Gurion University of the Negev), Ronit Gold(Tel Aviv University), Ofir Wolach(Tel Aviv University)
Cited by 31
Related Papers
Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium
|The Lancet Infectious Diseases|2019|1.7k
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Tracing the Evolutionary History and Global Expansion of Candida auris Using Population Genomic Analyses
|mBio|2020|445
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma
|Blood Advances|2021|170
Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy—A Single-Center Prospective Cohort Study
|Transplantation and Cellular Therapy|2021|164